SELLAS Life Sciences (SLS) 10-Q 9 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 31, 2016
Document Document And Entity Information [Abstract]
Entity Registrant Name	Galena Biopharma, Inc.
Trading Symbol	GALE
Entity Central Index Key	1,390,478
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		213,968,953

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 19,590	$ 29,730
Restricted cash	24,401	401
Litigation settlement insurance recovery	0	21,700
Prepaid expenses and other current assets	1,210	1,398
Current assets of discontinued operations, net	83	392
Total current assets	45,284	53,621
Equipment and furnishings, net	259	335
In-process research and development	12,864	12,864
GALE-401 rights	9,255	9,255
Goodwill	5,898	5,898
Deposits and other assets	218	171
Total assets	73,778	82,144
Current liabilities:
Accounts payable	1,273	1,597
Accrued expenses and other current liabilities	4,703	5,292
Litigation settlement payable	5,100	25,000
Fair value of warrants potentially settleable in cash	9,264	14,518
Current portion of long-term debt	23,157	4,739
Current liabilities of discontinued operations	3,727	5,925
Total current liabilities	47,224	57,071
Deferred tax liability	5,418	5,418
Contingent purchase price consideration	815	6,142
Total liabilities	53,457	68,631
Commitments and contingencies
Stockholders' equity:
Common stock, $0.0001 par value; 275,000,000 shares authorized, 182,996,385 shares issued and 182,321,385 shares outstanding at June 30, 2016; 162,581,753 shares issued and 161,906,753 shares outstanding at December 31, 2015	18	15
Additional paid-in capital	314,639	296,730
Accumulated deficit	290,487	279,383
Less treasury shares at cost, 675,000 shares	(3,849)	(3,849)
Total stockholders’ equity	20,321	13,513
Total liabilities and stockholders' equity	$ 73,778	$ 82,144

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	182,512,117	162,581,753
Common stock, shares outstanding	181,837,117	161,906,753
Treasury stock, shares	675,000	675,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Costs and expenses:
Research and development	$ 6,175	$ 7,197	$ 11,618	$ 13,022
General and administrative	3,117	1,886	6,642	4,973
Total operating expenses	9,292	9,083	18,260	17,995
Operating loss	(9,292)	(9,083)	(18,260)	(17,995)
Other income (expense):
Total settlements	(1,800)	0	(1,800)	0
Change in fair value of warrants potentially settleable in cash	14,392	(4,267)	10,520	(3,115)
Interest expense, net	(519)	(207)	(611)	(432)
Change In Fair Value Of Contingent Purchase Price Consideration	5,497	83	5,327	(238)
Total non-operating income (expense), net	17,570	(4,391)	13,436	(3,785)
Income (loss) from continuing operations	8,278	(13,474)	(4,824)	(21,780)
Loss from discontinued operations	(2,889)	(2,186)	(6,280)	(4,417)
Net income (loss)	$ 5,389	$ (15,660)	$ (11,104)	$ (26,197)
Net loss per common share:
Basic and diluted net loss per share, continuing operations (in dollars per share)	$ 0.05	$ (0.08)	$ (0.03)	$ (0.15)
Basic and diluted net loss per share, discontinued operations (in dollars per share)	(0.02)	(0.02)	(0.03)	(0.03)
Basic net loss per share (in dollars per share)	$ 0.03	$ (0.10)	$ (0.06)	$ (0.18)
Weighted-average common shares outstanding: basic and diluted	182,034,593	161,383,398	180,703,456	148,647,581
Weighted-average common shares outstanding: diluted (in shares)	185,477,330	161,383,398	180,703,456	148,647,581

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 6 months ended Jun. 30, 2016 - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Senior Notes [Member]Senior Secured Debentures [Member]	Senior Notes [Member]Senior Secured Debentures [Member]Additional Paid-in Capital [Member]
Beginning balance, shares at Dec. 31, 2015		162,581,753
Beginning balance at Dec. 31, 2015	$ 13,513	$ 15	$ 296,730	$ (279,383)	$ (3,849)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock, shares		19,772,727
Issuance of common stock	20,189	$ 3	20,186
Common stock warrants issued	(5,590)		(5,590)			$ (1,139)	$ (1,139)
Issuance of common stock upon exercise of warrants, shares		408,058
Issuance of common stock upon exercise of warrants	557	$ 0	557
Issuance of common stock in connection with employee stock purchase plan, shares		67,017
Issuance of common stock in connection with employee stock purchase plan	78		78
Stock-based compensation for directors and employees	$ 1,278		1,278
Exercise of stock options, shares	167,000	166,830
Exercise of stock options	$ 261		261
Net loss	(11,104)			(11,104)
Ending balance, shares at Jun. 30, 2016		182,996,385
Ending balance at Jun. 30, 2016	$ 20,321	$ 18	$ 314,639	$ (290,487)	$ (3,849)

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Statement of Cash Flows [Abstract]
Net loss from continuing operations	$ (4,824)	$ (21,780)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	777	181
Non-cash stock-based compensation	1,278	759
Change in fair value of common stock warrants	(10,520)	3,115
Change in fair value of contingent consideration	(5,327)	238
Changes in operating assets and liabilities:
Prepaid expenses and other assets	141	256
Litigation settlement insurance recovery	21,700	0
Litigation settlement payable	(19,900)	0
Accounts payable	(324)	(825)
Accrued expenses and other current liabilities	(589)	(1,380)
Net cash used in continuing operating activities	(17,588)	(19,436)
Net loss from discontinued operations	6,280	4,417
Changes in operating assets and liabilities attributable to discontinued operations	(839)	437
Net cash used in discontinued operating activities	(7,119)	(3,980)
Net cash used in operating activities	(24,707)	(23,416)
Cash flows from investing activities:
Cash paid for purchase of equipment and furnishings	(6)	(34)
Net cash used in continuing investing activities	(6)	(34)
Selling costs paid for sale of commercial assets	(1,050)
Cash paid for commercial assets		(534)
Net cash used in discontinued investing activities	(1,050)	(534)
Net cash used in investing activities	(1,056)	(568)
Cash flows from financing activities:
Net proceeds from issuance of common stock	20,189	47,416
Net proceeds from exercise of stock options	261	1
Proceeds from exercise of warrants	233	0
Proceeds from common stock issued in connection with ESPP	78	110
Net proceeds from issuance of long-term debt	23,641	0
Minimum cash covenant on long-term debt	(24,000)	0
Principal payments on long-term debt	(4,779)	(1,914)
Net cash provided by financing activities	15,623	45,613
Net (decrease) increase in cash and cash equivalents	(10,140)	21,629
Cash and cash equivalents at the beginning of period	29,730	23,650
Cash and cash equivalents at end of period	19,590	45,279
Supplemental disclosure of cash flow information:
Cash received during the periods for interest	49	2
Cash paid during the periods for interest	606	312
Supplemental disclosure of non-cash investing and financing activities:
Fair value of warrants issued in connection with common stock recorded as cost of equity	5,590	10,296
Reclassification of warrant liabilities upon exercise	$ (324)	$ 0

Business and Basis of Presentat

Business and Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Overview Galena Biopharma, Inc. (“we,” “us,” “our,” “Galena” or the “Company”) is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including our hematology asset, GALE-401, our novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S), GALE-301 and GALE-302. GALE-401 is a controlled release version of the approved drug anagrelide for the treatment of elevated platelets in patients with myeloproliferative neoplasms. GALE-401 has completed a Phase 2 trial and we are advancing the asset into a pivotal trial. NeuVax is currently in multiple Phase 2 trials. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b clinical trial given sequentially with GALE-302. We are seeking to build value for shareholders through pursuit of the following objectives: • Developing hematology and oncology assets through clinical development, targeting areas of unmet medical need. Our hematology asset is targeting the treatment of patients with essential thrombocythemia (ET) to reduce elevated platelet counts . Our immunotherapy programs are currently targeting two key areas: secondary prevention intended to significantly decrease the risk of disease recurrence in breast, gastric, and ovarian cancers; and primary prevention intended to cease or delay ductal carcinoma in situ (DCIS) from becoming invasive breast cancer. • Expand our development pipeline by enhancing the clinical and geographic footprint of our technologies. We intend to accomplish this through the initiation of new clinical trials and potentially through the acquisition of additional development programs. • Leverage partnerships and collaborations, as well as investigator-sponsored trial arrangements, to maximize the scope of potential clinical opportunities in a cost effective and efficient manner. Basis of Presentation and Significant Accounting Policies The accompanying consolidated financial statements included herein have been prepared by Galena pursuant to the generally accepted accounting principles (GAAP). Unless the context otherwise indicates, references in these notes to the “Company,” “we,” “us” or “our” refer (i) to Galena, our wholly owned subsidiaries, Apthera, Inc., or “Apthera,” and our wholly owned subsidiary, Mills Pharmaceuticals, LLC or "Mills." At June 30, 2016 , the Company’s capital resources consisted of cash and cash equivalents of $19.6 million not including $24.4 million of restricted cash. The Company will need to continue to incur significant expenses to advance our development portfolio and will need to raise additional capital to finance such activities. On July 13, 2016, we closed the sale to certain institutional investors of 28,000,000 shares of common stock at a purchase price per share of $0.45 in a registered direct offering, and warrants to purchase up to 14,000,000 shares of common stock with an exercise price of $0.65 per share in a concurrent private placement. The warrants are initially exercisable six months and one day following issuance and have a term of five years from the date of issuance. The net proceeds to Galena after deducting placement agent fees and estimated offering expenses were approximately $11.7 million . The Company intends to use the net proceeds from this offering to fund its clinical trials of its product candidates, to augment its working capital, and for general corporate purposes. The current unrestricted cash and cash equivalents as of the date of this filing will fund the Company's operations for at least six months. Additional funding was received July 13, 2016 upon the closing of an underwritten registered direct offering of our common stock and a private placement of warrants for net proceeds of $11.7 million to the Company. Additional funding sources that are, or in certain circumstances may be, available to the Company, include 1) approximately $24 million of restricted cash associated with our $25.5 million sale of Debentures by amending the current agreement with the holder to reduce the minimum cash covenant as detailed in Note 4; 2) a Purchase Agreement with Lincoln Park Capital, LLC; and 3) At Market Issuance Sales Agreements (ATM) with FBR & Co. (formerly MLV & Co. LLC) and Maxim Group LLC. The Purchase Agreement and ATM are unavailable to the Company until 75 days after the closing of our July 2016 financing. The Company cannot provide assurances that its plans will not change or that changed circumstances will not result in the depletion of its capital resources more rapidly than it currently anticipates. The Company is seeking and will need to raise additional capital, whether through a sale of equity or debt securities, a strategic business, the establishment of other funding facilities, licensing arrangements, asset sales or other means, in order to continue the development of the Company's product candidates and to support its other ongoing activities. However, the Company cannot be certain that it will be able to raise additional capital on favorable terms, or at all, which raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Discontinued Operations — As described in Note 11, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets. Uses of Estimates in Preparation of Financial Statements — The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates. Principles of Consolidation — The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation. Reclassifications — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share. The Company has reclassified the financial information for the three and six months ended June 30, 2015 to present the Company's commercial business as discontinued operations in the accompanying financial statements as the commercial business was divested in the fourth quarter of 2015. Cash and Cash Equivalents — The Company considers all highly liquid debt instruments with an original maturity of 90 days or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits. Restricted Cash — Restricted cash consists of certificates of deposit on hand with the Company’s financial institutions as collateral for its corporate credit cards and the minimum cash covenant per the Company's outstanding Debentures as described in Note 4. Fair Value of Financial Instruments — The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest. Equipment and Furnishings — Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years) of the related assets. Goodwill and Intangible Assets — Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the Company considers important that could trigger an interim review for impairment include, but are not limited to, the following: • Significant changes in the manner of its use of acquired assets or the strategy for its overall business; • Significant negative industry or economic trends; • Significant decline in stock price for a sustained period; and • Significant decline in market capitalization relative to net book value. Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach. Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company’s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts. In connection with the interim analysis of the PRESENT Phase 3 clinical trial and subsequent close down of the trial, the Company performed an impairment analysis of the intangible asset and goodwill. The fair value was determined to exceed to the carrying amount as of June 30, 2016 based on the other ongoing and and planned trials with NeuVax. As a result, no impairment was deemed necessary to these assets as of June 30, 2016. Acquisitions and In-Licensing — For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of June 30, 2016 , we determined there were no variable interest entities required to be consolidated. We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition. Contingent Purchase Price Consideration — Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss. Patents and Patent Application Costs — Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred. Litigation Settlement Payable and Insurance Recoveries — There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable. Share-based Compensation — The Company follows the provisions of the FASB ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (“ASC 505-50”), Equity Based Payments to Non- Employees . Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested. Research and Development Expenses — Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses. Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved. The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site. Income Taxes — The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC 740-10, Accounting for Income Taxes (“ASC 740-10”). These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. ASC 740-10 requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company’s income tax provision or benefit. The recognition and measurement of benefits related to the Company’s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company’s assumptions or changes in the company’s assumptions in future periods are recorded in the period they become known. There was no income tax expense or benefit for the three and six month periods ended June 30, 2016 and 2015. We continue to maintain a full valuation allowance against our net deferred tax assets. Concentrations of Credit Risk — Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of June 30, 2016 , the Company’s cash equivalents were invested in money market mutual funds. The Company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits. Comprehensive Loss — Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented. Effect of Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 provides accounting guidance for both lessee and lessor accounting models. Among other things, lessees will recognize a right-of-use asset and a lease liability for leases with a duration of greater than one year. For income statement purposes, ASU 2016-02 will require leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. The new standard will be effective for us on January 1, 2019 and will be adopted using a modified retrospective approach which will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures, however, we anticipate recognition of additional assets and corresponding liabilities related to leases on our balance sheet upon adoption. In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation ("ASU 2016-09"). ASU 2016-09 changes several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, employee tax withholding, calculation of shares for use in diluted earnings per share, and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. Early adoption is available. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company follows ASC 820, Fair Value Measurements and Disclosures , (“ASC 820”) for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows: Level 1 — quoted prices in active markets for identical assets or liabilities. Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. The Company categorized its cash equivalents as Level 1. The valuations for Level 1 were determined based on a “market approach” using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level 2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC 718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued. The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands): Description June 30, 2016 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 18,169 $ 18,169 $ — $ — Total assets measured and recorded at fair value $ 18,169 $ 18,169 $ — $ — Liabilities: Warrants potentially settleable in cash $ 9,264 $ — $ 9,264 $ — Contingent purchase price consideration 815 — — 815 Total liabilities measured and recorded at fair value $ 10,079 $ — $ 9,264 $ 815 Description December 31, 2015 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 29,171 $ 29,171 $ — $ — Total assets measured and recorded at fair value $ 29,171 $ 29,171 $ — $ — Liabilities: Warrants potentially settleable in cash $ 14,518 $ — $ 14,518 $ — Contingent purchase price consideration 6,142 — — 6,142 Total liabilities measured and recorded at fair value $ 20,660 $ — $ 14,518 $ 6,142 The Company did not transfer any financial instruments into or out of Level 3 classification during the six months ended June 30, 2016 and 2015. A reconciliation of the beginning and ending Level 3 liabilities for the six months ended June 30, 2016 is as follows (in thousands): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, January 1, 2016 $ 6,142 Change in the estimated fair value of the contingent purchase price consideration (5,327 ) Balance at June 30, 2016 $ 815 The fair value of the contingent purchase price consideration is measured at the end of each reporting period using Level 3 inputs in a probability-weighted, discounted cash-outflow model. The significant unobservable assumptions include the probability of achieving each milestone, the date we expect to reach the milestone, and a determination of present value factors used to discount future expected cash outflows. The change in the estimated fair value of the contingent purchase price consideration during the quarter ended June 30, 2016 reflects an adjusted probability and time line for the potential approval of NeuVax associated with the Phase 2 combination trial with trastuzumab. Previously, the valuation was measured using the probability and time line of the Phase 3 PRESENT trial, which was stopped in June 2016 due to futility as recommended by the Independent Data Monitoring Committee ("IDMC"). See Note 7 for discussion of the Level 2 liabilities relating to warrants accounted for as liabilities.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands): June 30, 2016 December 31, 2015 Clinical trial costs $ 3,208 $ 3,294 Professional fees 560 435 Compensation and related benefits 935 1,535 Interest expense — 28 Accrued expenses and other current liabilities $ 4,703 $ 5,292

Long-term Debt

Long-term Debt	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Long-term Debt	Long-term Debt On May 8, 2013, we entered into a loan and security agreement with Oxford Finance LLC, as collateral agent, and related lenders under which we borrowed the first tranche of $10 million (the "Loan"). The Loan payment terms include 12 months of interest-only payments at the fixed coupon rate of 8.45% , followed by 30 months of amortization of principal and interest until maturity in November 2016. In connection with the Loan, we paid the lender a 1% cash facility fee and a 5.5% cash final payment and granted to the lenders seven -year warrants to purchase up to 182,186 shares of our common stock at an exercise price of $2.47 , which equaled a 20 -day average market price of our common stock prior to the date of the grant. On May 10, 2016, the Company prepaid the outstanding principal amount and cash final payment. On May 10, 2016, the Company entered into a Securities Purchase Agreement, with certain purchasers pursuant to which the Company sold, at a 6.375% original issue discount, a total of $25,530,000 Senior Secured Debentures (the “Debentures”) and warrants to purchase up to 2.0 million shares of the Company's common stock. Net proceeds to the Company from sale of the Debentures, after payment of commissions and legal fees, were approximately $23,400,000 . The Debentures mature November 10, 2018, accrue interest at 9% per year, and do not contain any conversion features into shares of our common stock. The Company intends to use the net proceeds from this offering to fund the costs associated with the close down of the Phase 3 PRESENT study of NeuVax and other clinical trials of our product candidates and to augment its working capital and for general corporate purposes. The Debentures carry an interest only period of six months following which the holder shall have the rights, at its option, to require the Company to redeem up to $1,100,000 per month of the outstanding principal amount of these Debentures. Interest is payable at the end of each month based on the outstanding principal. The Company is required to promptly, but in any event no more than three trading days after the holder delivers a redemption notice to the Company, pay the applicable redemption amount in cash or, at the Company’s election and subject to certain conditions, in shares of the Company's common stock. If the Company elects to pay the redemption amount in shares of its common stock, then the shares will be delivered at the lesser of A) 7.5% discount to the average of the 3 lowest volume weighted average prices over the prior 20 trading days or B) a 7.5% discount to the prior trading day’s volume weighted average price. The Company may only opt for payment in shares of common stock if certain equity conditions are met. The Company, at its option, may also force the holder to redeem up to double the monthly redemption principal amount of the Debentures but not less than the monthly payment. Based on the recommendation of the IDMC to stop the PRESENT Trial, the holder has the right to require the Company to prepay in cash all, or any portion, of the outstanding principal amount of this Debenture funded in cash by the holder on the closing date, plus all accrued and unpaid interest. If the holder elects such prepayment of the Debentures, then the number of shares subject to the warrants issued to the holder will be reduced in proportion to the percentage of principal required and accrued interest to be prepaid by the Company. The Purchaser received 1 million warrants upon the closing on the sale of the Debentures at an exercise price of $1.51 , maturing 5 years from issuance. Additionally, the Purchasers received 1 million warrants upon the Company's public company announcement of the interim analysis on June 29, 2016 at an exercise price of $0.43 . As of June 30, 2016 and the date of this filing, the holder had not exercised its right to require the Company to prepay in cash all, or any portion, of the outstanding principal amount of the Debentures. The holder's right to require the Company to prepay the outstanding principal amount expires 30 trading days after June 29, 2016, the announcement date of the recommendation of the IDMC. Therefore as of June 30, 2016 the Debentures, net of unamortized discounts, are presented as current liabilities on the condensed consolidated balance sheet. The Company’s obligations under the Debenture can be accelerated in the event the Company undergoes a change in control and other customary events of default. In the event of default and acceleration of the Company’s obligations, the Company would be required to pay all amounts of principal and interest then outstanding under the Debenture in cash. The Company’s obligations under the Debentures are secured under a Security Agreement by a senior lien on all of the Company’s assets, including all of the Company’s interests in its consolidated subsidiaries. Until the holder exercises its right to require the Company to prepay some or all of the loan, the Company must also maintain a minimum of $24.0 million in cash, which is included in restricted cash as of June 30, 2016. Armentum Partners, LLC (the “Placement Agent”) acted as the placement agent in the offering of the Debentures and the Company agreed to pay the Placement Agent a fee equal to 2% of the funds received from the sale of the Debentures. The Company paid half of the placement fee upon funding with the remaining payable at such time as the IDMC recommended in favor of the continuation of the PRESENT Trial or the holder waives the Company’s obligation to prepay the Debenture as a result of the IDMC’s recommendation .

Legal Proceedings, Commitments

Legal Proceedings, Commitments and Contingencies (Notes)	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings, Commitments and Contingencies	Legal Proceedings, Commitments and Contingencies Legal Proceedings On December 3, 2015, we agreed in principle to resolve and settle the consolidated shareholder derivative action, In re Galena Biopharma, Inc. Derivative Litigation , Civil Action No. 3:14-cv-00382-SI, pending in the United States District Court for the District of Oregon against us and certain of our current and former officers and directors. On April 21, 2016, the District Court of Oregon held the final approval hearing of the settlement with the derivative plaintiffs after which the District Court continued the final approval hearing until June 23, 2016 and requested the parties submit additional briefing by June 9, 2016 on the fee request by the derivative plaintiffs’ attorneys. Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and judgment in In re Galena Biopharma, Inc. Derivative Litigation , granting final approval to the settlement. On the same day, the Court also issued an opinion and order awarding attorney’s fees of $4.5 million plus costs, which will be paid by our insurance carriers. The settlement includes a payment of $15 million in cash by our insurance carriers, which we used to fund a portion of the class action settlement, and cancellation of 1,200,000 outstanding director stock options. The settlement also requires that we adopt and implement certain corporate governance measures. The settlement does not include any admission of wrongdoing or liability on the part of us or the individual defendants and includes a full release of us and the current and former officers and directors in connection with the allegations made in the consolidated federal derivative actions and state court derivative actions. On December 3, 2015, we also agreed in principal to resolve and settle the securities putative class action lawsuit, In re Galena Biopharma, Inc. Securities Litigation , Civil Action No. 3:14-cv-00367-SI, pending against us, certain of our current and former officers and directors and other defendants in the United States District Court for the District of Oregon. Following the hearing on June 23, 2016, on June 24, 2016, the U.S. District Court for the District of Oregon entered a final order and partial judgment in In re Galena Biopharma, Inc. Securities Litigation , granting final approval of the settlement. On the same day, the Court also issued an opinion and order awarding attorney’s fees of $4.5 million plus costs, which is paid out of the settlement funds. The settlement agreement provides for a payment of $20 million to the class and the dismissal of all claims against us and our current and former officers and directors in connection with the consolidated federal securities class actions. Of the $20 million settlement payment to the class, $16.7 million was paid by our insurance carriers and $2.3 million in cash was paid by us on July 1, 2016, along with $1 million in shares of our common stock ( 480,053 shares) paid by us on July 6, 2016. We will be responsible for defense costs and any settlements or judgments incurred for any related opt-out lawsuits. As of June 30, 2016 our insurance carriers paid $21.7 million . The Company paid $2.3 million in cash and $1 million in common stock on July 1, 2016. In July 2016, we have resolved claims brought by shareholders that relate to the securities litigation mentioned above in one case for $150,000 plus $150,000 in shares ( 291,262 ) of our common stock, and in another case for $1.5 million in shares of our common stock ( 3,366,750 shares). The shares issued in connection with such settlements are included in the secondary offering filed on July 25, 2016. The settlements do not include any admission of wrongdoing or liability on the part of us or any of the current or former directors and officers and includes a full release of us and the current and former directors and officers in connection with the allegations made. We are not aware of any other claims made by shareholders who have opted out of the securities litigation. The litigation settlements are summarized as follow as of June 30, 2016 (in thousands) Amount Class action settlement $ 20,000 Derivative settlement 5,000 Shareholders securities litigation settlements $ 1,800 Total settlements $ 26,800 Paid by the insurance carriers $ 21,700 Payable by the company in cash (paid in July 2016) 2,450 Payable by the company in common stock (paid in July 2016) 2,650 Total settlements $ 26,800 We are aware that the SEC is investigating certain matters relating to the use of certain outside investor-relations professionals by us and other public companies. We have been in contact with the SEC staff through our counsel and are cooperating with the investigation and in discussions with the SEC staff to resolve the investigation. A federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes. The criminal trial is set for October 2016. We have received a trial subpoena for documents in connection with that investigation and we have been in contact with the U.S. Attorney’s Office for the Southern District of Alabama, which is handling the criminal trial, and are cooperating in the production of documents. On April 28, 2016, a second superseding indictment was filed in the criminal case, which added additional information about the defendant physicians and provided information regarding the facts and circumstances involving a rebate agreement between the Company and the defendant physicians’ pharmacy as well as their ownership of our stock. Certain former employees have received trial subpoenas to appear at the trial and provide oral testimony. We have agreed to reimburse those former employees’ attorney’s fees. To our knowledge, we are not a target or subject of that investigation. There also have been federal and state investigations of a company that has a product that competes with Abstral in the same therapeutic class, and we have learned that the FDA and other governmental agencies are investigating our Abstral promotion practices. On December 16, 2015, we received a subpoena issued by the U.S. Attorney’s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral. We have been in contact with the U.S. Attorney’s Office for the District of New Jersey and are cooperating in the production of the requested documents. We are unable to predict whether we could become subject to legal or administrative actions as a result of these matters, or the impact of such matters. If we are found to be in violation of the False Claims Act, Anti-Kickback Statute, Patient Protection and Affordable Care Act, or any other applicable state or any federal fraud and abuse laws, we may be subject to penalties, such as civil and criminal penalties, damages, fines, or an administrative action of exclusion from government health care reimbursement programs. We can make no assurances as to the time or resources that will need to be devoted to these matters or their outcome, or the impact, if any, that these matters or any resulting legal or administrative proceedings may have on our business or financial condition.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity Preferred Stock — The Company has authorized up to 5,000,000 shares of preferred stock, $0.0001 par value per share, for issuance. The preferred stock will have such rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, as shall be determined by the Company’s Board of Directors upon its issuance. To date, the Company has not issued any preferred shares. Common Stock — The Company has authorized up to 275,000,000 shares of common stock, $0.0001 par value per share, for issuance. On July 14, 2016, shareholders approved a 75,000,000 share increase to the Company's authorized shares of common stock up to 350,000,000 shares. November 2014 Purchase Agreement with Lincoln Park Capital, LLC - On November 18, 2014, the Company entered into a purchase agreement with Lincoln Park Capital, LLC (LPC), pursuant to which the Company has the right to sell to LPC up to $50 million in shares of the Company's common stock, subject to certain limitations and conditions over the 36 month term of the purchase agreement. Pursuant to the purchase agreement, LPC initially purchased 2.5 million shares of the Company's common stock at $2.00 per share and the Company issued 631,221 shares of common stock to LPC as a commitment fee, which was recorded as a cost of capital. As a result of this initial issuance, the Company received initial net proceeds of $4.9 million , after deducting commissions and other offering expenses. In addition to LPC’s initial purchase of our common stock under the purchase agreement, during the first quarter of 2015, we received net proceeds of $4.4 million from LPC’s subsequent purchases of a total of 2.7 million shares of our common stock, excluding the commitment fee shares. There were no sales of our common stock under the LPC purchase agreement during the six months ended June 30, 2016. At Market Issuance Sales Agreements - On May 24, 2013 the Company entered into At Market Issuance Sales Agreements (ATM) with FBR & Co. (formerly MLV & Co. LLC) and Maxim Group LLC (the Agents). From time to time during the term of the ATM, we may issue and sell through the Agents, shares of our common stock, and the Agents collect a fee equal to 3% of the gross proceeds from the sale of shares, up to a total limit of $20 million in gross proceeds. The ATM is available to the Company until it is terminated by the Agents or the Company. During the first quarter of 2015, we received $2.3 million in net proceeds from the sale of 1.4 million shares of our common stock through the ATM. There were no sales of our common stock under the ATM during the six months ended June 30, 2016. March 2015 Underwritten Public Offering - On March 18, 2015 the Company closed an underwritten public offering of 24,358,974 units at a price to the public of $1.56 per unit for gross proceeds of $38 million (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase 0.50 of a share of common stock at an exercise price of $2.08 per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional 3,653,846 shares of common stock and/or warrants to purchase up to 1,826,923 shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of 1,826,923 shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase 3,653,846 shares of common stock for additional net proceeds of $5.4 million . The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were $40.8 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. January 2016 Underwritten Public Offering - On January 12, 2016 the Company closed an underwritten public offering of 19,772,727 units at a price to the public of $1.10 per unit for gross proceeds of $21.8 million (the "January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase 0.60 of a share of common stock at an exercise price of $1.42 per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional 2,965,909 shares of common stock and/or warrants to purchase up to 1,779,545 shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of 1,779,545 shares of common stock. The underwriters did not exercise their over-allotment option to purchase 2,965,909 shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were $20.2 million , after deducting underwriting discounts and commissions and offering expense paid by the Company. Shares of common stock for future issuance are reserved for as follows (in thousands): As of June 30, 2016 Warrants outstanding 37,418 Stock options outstanding 10,309 Options reserved for future issuance under the Company’s 2007 Incentive Plan 10,923 Shares reserved for future issuance under the Employee Stock Purchase Plan 461 Total reserved for future issuance 59,111

Warrants

Warrants	6 Months Ended
	Jun. 30, 2016
Warrants and Rights Note Disclosure [Abstract]
Warrants	Warrants The following is a summary of warrant activity for the six months ended June 30, 2016 (in thousands): January 2016 Warrants March 2015 Warrants September 2013 Warrants December 2012 Warrants Other Equity Financing Warrants Warrants issued to Consultants and Debtors Total Outstanding, January 1, 2016 — 14,006 3,973 3,031 816 482 22,308 Issued 13,643 — — — — 2,000 15,643 Exercised — — — — (502 ) — (502 ) Expired — — — — (31 ) — (31 ) Outstanding, June 30, 2016 13,643 14,006 3,973 3,031 283 2,482 37,418 Expiration January 2021 March 2020 September 2018 December 2017 Varies 2016-2017 Varies 2014-2021 Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants. Warrants classified as liabilities Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in January 2016, March 2015, September 2013, December 2012, April 2011, March 2011, and March 2010. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock. The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of operations as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs: As of June 30, 2016 January 2016 Warrants March 2015 Warrants September 2013 Warrants December 2012 Warrants April 2011 Warrants March 2010 Warrants Strike price $ 1.42 $ 2.08 $ 2.50 $ 1.75 $ 0.65 $ 1.92 Expected term (years) 4.52 3.72 2.22 1.48 0.81 0.25 Volatility % 113.70 % 122.36 % 139.26 % 167.41 % 218.93 % 218.93 % Risk-free rate % 0.94 % 0.82 % 0.61 % 0.51 % 0.42 % 0.19 % As of December 31, 2015 March 2015 Warrants September 2013 Warrants December 2012 Warrants April 2011 Warrants March 2011 Warrants* March 2010 Warrants Strike price $ 2.08 $ 2.50 $ 1.83 $ 0.65 $ 0.65 $ 2.02 Expected term (years) 4.22 2.72 1.98 1.31 0.18 1.00 Volatility % 75.85 % 74.70 % 76.37 % 65.60 % 47.98 % 71.41 % Risk-free rate % 1.58 % 1.24 % 1.05 % 0.77 % — % — % *The March 2011 warrants expired in March 2016. The March 2010 warrants do not expire until September 2016. The expected volatility assumptions are based on the Company's implied volatility in combination with the implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the Company has no present intention to pay cash dividends. The changes in fair value of the warrant liability for the six months ended June 30, 2016 were as follows (in thousands): January 2016 Warrants March 2015 Warrants September 2013 Warrants December 2012 Warrants April 2011 Warrants Other Equity Financing Warrants Total Warrant liability, January 1, 2016 $ — $ 10,337 $ 1,933 $ 1,565 $ 537 $ 146 $ 14,518 Fair value of warrants issued 5,590 — — — — — 5,590 Fair value of warrants exercised — — — — (278 ) (46 ) (324 ) Change in fair value of warrants (1,515 ) (6,668 ) (1,148 ) (909 ) (184 ) (96 ) (10,520 ) Warrant liability, June 30, 2016 $ 4,075 $ 3,669 $ 785 $ 656 $ 75 $ 4 $ 9,264 Warrants classified as equity Equity-classified warrants consist of warrants issued in connection with consulting services provided to us and warrants issued in connection with debt financings. On May 10, 2016 upon closing on the sale of Debentures, we granted the holder warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $1.51 . The warrants were valued using an appropriate pricing model. The fair value assumptions for the grant included a volatility of 77.13% , expected term of five and five tenths years, risk-free rate of 1.26% , and a dividend rate of 0.00% . The fair value of the warrants granted was $0.87 per share. These warrants are recorded in equity at fair value upon issuance. Additionally, on June 29, 2016 upon closing on the public announcement of the interim analysis of the PRESENT trial, we granted the holder warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $0.43 .The warrants were valued using an appropriate pricing model. The fair value assumptions for the grant included a volatility of 106.63% , expected term of 5.5 years, risk-free rate of 1.35% , and a dividend rate of 0.00% . The fair value of the warrants granted was $0.27 per share. These warrants are recorded in equity at fair value upon issuance.

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Based Compensation	Stock-Based Compensation Options to Purchase Shares of Common Stock — The Company follows the provisions ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options and warrants granted in consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of ASC Topic 505-50. Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options and warrants are fully vested. The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2016 and 2015, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Research and development $ 108 $ 93 $ 235 $ 170 General and administrative 514 296 1,043 590 Total stock-based compensation from continuing operations $ 622 $ 389 $ 1,278 $ 760 The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Risk free interest rate 1.41 % 1.69 % 1.41 % 1.50 % Volatility 76.30 % 73.32 % 75.63 % 74.20 % Expected lives (years) 6.25 5.76 6.25 6.09 Expected dividend yield — % — % — % — % The weighted-average fair value of options granted during the three and six months ended June 30, 2016 were $1.36 per share and $0.86 per share, respectively. The Company’s expected common stock price volatility assumption is based upon the Company's own implied volatility in combination with the implied volatility of a basket of comparable companies. The expected life assumptions for employee grants were based upon the simplified method provided for under ASC 718-10, which averages the contractual term of the Company’s options of ten years with the average vesting term of four years for an average of six years . The expected life assumptions for non-employees were based upon the contractual term of the option. The dividend yield assumption is zero, because the Company has never paid cash dividends and presently has no intention to do so. The risk-free interest rate used for each grant was also based upon prevailing short-term interest rates. The Company has estimated an annualized forfeiture rate of 15% for options granted to its employees, 8% for options granted to senior management and zero for non-employee directors. The Company will record additional expense if the actual forfeitures are lower than estimated and will record a recovery of prior expense if the actual forfeiture rates are higher than estimated. As of June 30, 2016 , there was $3,755,000 of unrecognized compensation cost related to outstanding options that is expected to be recognized as a component of the Company’s operating expenses over a weighted-average period of 2.79 years. As of June 30, 2016 , an aggregate of 26,500,000 shares of common stock were reserved for issuance under the Company’s 2007 Incentive Plan, including 10,309,000 shares subject to outstanding common stock options granted under the plan. On July 14, 2016, the shareholders approved the 2016 Incentive Plan into which the available shares in the 2007 Incentive Plan were transferred. There are 10,923,000 shares available for future grants based on adjustments in the 2016 Incentive Plan. The administrator of the plan determines the terms when an option may become exercisable. Vesting periods of options granted to date have not exceeded four years . The options will expire, unless previously exercised, no later than ten years from the grant date. The following table summarizes option activity of the Company: Total Number of Shares (In Thousands) Weighted Average Exercise Price Aggregate Intrinsic Value (In Thousands) Outstanding at January 1, 2016 13,262 $ 2.58 Granted 166 1.27 Exercised (167 ) 1.57 $ 56 Canceled (2,952 ) 3.07 $ — Outstanding at June 30, 2016 10,309 $ 2.44 $ — Options exercisable at June 30, 2016 5,970 $ 2.97 $ — The aggregate intrinsic values of outstanding and exercisable options at June 30, 2016 were calculated based on the closing price of the Company’s common stock as reported on The NASDAQ Capital Market on June 30, 2016 of $0.47 per share. The aggregate intrinsic value equals the positive difference between the closing fair market value of the Company’s common stock and the exercise price of the underlying options.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Net Loss Per Share	Net Income (Loss) Per Share Basic and diluted earnings per share are calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Numerator: Net income (loss) (in thousands) $ 5,389 $ (15,660 ) $ (11,104 ) $ (26,197 ) Denominator: Weighted average number of common shares outstanding 182,034,593 161,383,398 180,703,456 148,647,581 Effect of dilutive securities Stock options 677,279 — — — Warrants 2,765,458 — — — Dilutive potential common shares 3,442,737 — — — Shares used in calculating diluted earnings per share 185,477,330 161,383,398 180,703,456 148,647,581 Basic net income (loss) per share $ 0.03 $ (0.10 ) $ (0.06 ) $ (0.18 ) Diluted net income (loss) per share $ 0.03 $ (0.10 ) $ (0.06 ) $ (0.18 ) The following table sets forth the potentially dilutive common shares excluded from the calculation of net income (loss) per common share because their inclusion would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Warrants to purchase common stock 21,517 22,308 37,418 22,308 Options to purchase common stock 6,442 11,411 10,309 11,411 Total 27,959 33,719 47,727 33,719

License Agreements

License Agreements	6 Months Ended
	Jun. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
License Agreements	License Agreements As part of its business, the Company enters into licensing agreements with third parties that often require milestone and royalty payments based on the progress of the licensed assets through development and commercial stages. Milestone payments may be required, for example, upon approval of the product for marketing by a regulatory agency, and the Company may be required to make royalty payments based upon a percentage of net sales of the product. The expenditures required under these arrangements in any period may be material and are likely to fluctuate from period to period. These arrangements sometimes permit the Company to unilaterally terminate development of the product and thereby avoid future contingent payments; however, the Company is unlikely to cease development if the compound successfully achieves clinical testing objectives. On January 12, 2014, we acquired worldwide rights to anagrelide controlled release (CR) formulation, which we renamed GALE-401, through our acquisition of Mills Pharmaceuticals, LLC ("Mills") and Mills became a wholly owned subsidiary. GALE-401 contains the active ingredient anagrelide, an FDA-approved product that has been in use since the late 1990s for the treatment of essential thrombocythemia (ET). Mills holds an exclusive license to develop and commercialize anagrelide CR formulation, pursuant to a license agreement with BioVascular, Inc. Under the terms of the license agreement, Mills has agreed to pay BioVascular, Inc. a mid-to-low single digit royalty on net revenue from the sale of licensed products as well as future cash milestone payments based on the achievement of specified regulatory milestones. Mills is also responsible for patent prosecution and maintenance. BioVascular has advised the Company of an alleged breach of the BioVascular agreement which the Company has denied. Both parties are discussing the dispute and it is anticipated that the dispute will be resolved. On November 19, 2015, the Company and Sentynl Therapeutics Inc., a Delaware corporation (“Sentynl”), entered into and closed upon an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell to Sentynl and Sentynl agreed to purchase from the Company, certain assets of the Company related to and including its Abstral ® (fentanyl) sublingual tablets product (“Abstral”). The assets sold and assigned to Sentynl pursuant to the Purchase Agreement included all of the Company’s rights and interests in the Asset Purchase Agreement by and between the Company and Orexo AB (“Orexo”) dated March 15, 2013, and the License Agreement by and between the Company and Orexo dated March 18, 2013 (collectively, the “Orexo Agreements”). The Company’s future obligations under the Orexo Agreements were assumed by Sentynl pursuant to such assignment. In connection with such assignment, Orexo released the Company from any future obligations under the Orexo Agreements. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Abstral, as well for certain channel liabilities and rebates related to Abstral for a period of time post-closing. The total potential consideration payable to the Company under the Purchase Agreement is $12 million , comprised of an $8 million upfront payment and up to an aggregate of $4 million , consisting of two one-time payments based on Sentynl's achievement of "net sales" of Abstral in amounts ranging from $25 million to $35 million . On December 17, 2015, the Company and Midatech Pharma PLC, a public limited company organized under the laws of England and Wales (“Midatech”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company agreed to sell to Midatech and Midatech agreed to purchase from the Company, certain assets of the Company related to and including its Zuplenz ® (ondansetron) Oral Soluble Film (“Zuplenz”). The assets to be sold and assigned to Midatech pursuant to the Purchase Agreement include all of the Company’s rights and interests in the License and Supply Agreement by and between the Company and MonoSol Rx, LLC (“MonoSol”) dated July 17, 2014 (the “MonoSol License”). The Company’s future obligations under the MonoSol agreement will be assumed by Midatech pursuant to such assignment. The Purchase Agreement further provides that the Company will continue to be responsible for any pre-closing liabilities and obligations related to Zuplenz, as well for certain rebates and channel liabilities related to Zuplenz for a period of time post-closing. The transaction was completed on December 24, 2015. The total potential consideration payable to the Company under the Purchase Agreement is $29.75 million , comprised of an $3.75 million upfront payment upon the closing and up to an aggregate of $26 million , consisting of four one-time payments based on Midatech's achievement of "net sales" of Zuplenz in amounts ranging from $12 million to $70 million . Through a separate agreement with MonoSol entered into on December 16, 2015 (the “MonoSol License Amendment”), (i) the Company and MonoSol agreed to amend the MonoSol License in order to reduce the number of field representatives that the Company is required to maintain with respect to Zuplenz, and (ii) the Company paid MonoSol $900,000 of the upfront fee payable to the Company under the Purchase Agreement and 20% of any future milestone payments received by the Company under the Purchase Agreement. On December 24, 2015, the Company and Midatech closed upon the Purchase Agreement. In connection with the closing of the transactions contemplated by the Purchase Agreement, the Company assigned to Midatech all of its rights to and interests in the Company’s License and Supply Agreement, dated July 17, 2014 (the “MonoSol License”). As a result of such assignment, Midatech assumed all of the Company’s obligations under the MonoSol License.

Discontinued Operations, Assets

Discontinued Operations, Assets Held for Sale (Notes)	6 Months Ended
	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations,Assets Held for Sale	Discontinued Operations, Assets Held for Sale During the fourth quarter of 2015, The Company sold its rights to its commercial products Abstral ® (fentanyl) Sublingual Tablets and Zuplenz ® (ondansetron) Oral Soluble Film. The Company entered into an agreement with a third party firm to assist the company with the divestiture of its commercial operations including identifying potential acquirers. Pursuant to the terms of the agreement, the Company paid a success fee to the third party firm in an amount of $900,000 and agreed to pay 5% of realized future revenue and payment streams. The Company entered into compensatory arrangements related to the divestiture of our commercial business with certain members of commercial management. Under the terms of these arrangements, the Company paid a retention fee to the three employees in a combined total amount equal to $352,000 or 3% of cash consideration received as upfront payment in the transactions. These employees also received severance payments equal to one month’s salary for between four and seven months. In addition to these compensatory agreements loss from discontinued operations includes one-time termination benefits provided to employees who were part of the commercial business and did not accept employment opportunities at the companies that purchased Abstral and Zuplenz. The following table describes the net proceeds from the sale and the assets and liabilities sold, net of selling costs (in thousands): Sale of Abstral and related assets on November 19, 2015 Sale of Zuplenz and related assets on December 24, 2015 Net proceeds from sales Total consideration $ 8,348 $ 3,750 Less selling costs* (815 ) (1,050 ) Proceeds from sale, net of selling costs $ 7,533 $ 2,700 *Selling costs related to the sale of Zuplenz and related assets were included in accrued liabilities as of December 31, 2015 and were paid in the first quarter of 2016. All other amounts were received or paid in the fourth quarter of 2015. In addition to the upfront proceeds received from the sale of Abstral and Zuplenz and their related assets, the Company is eligible to receive up to $30 million in future milestone payments based on future net revenue of the products. The additional consideration will be recognized in the period that the net revenue milestones are achieved. The following table presents amounts related to the discontinued operations in the balance sheets (in thousands): June 30, 2016 December 31, 2015 Carrying amounts of assets included as part of discontinued operations: Accounts receivable, net $ 83 $ 392 Total current assets of discontinued operations, net 83 392 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable $ 1,299 $ 1,491 Accrued expenses and other current liabilities 2,428 4,434 Total current liabilities of discontinued operations $ 3,727 $ 5,925 The following table represents the components attributable to the commercial operations that are presented in the condensed consolidated statements of operations as discontinued operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net revenue $ — $ 3,382 $ — $ 6,132 Additional channel obligations (656 ) — (1,666 ) — Cost of revenue — (468 ) — (861 ) Amortization of certain acquired intangible assets — (442 ) — (588 ) Research and development — (94 ) — (179 ) Selling, general, and administrative (2,233 ) (4,581 ) (4,614 ) (8,921 ) Non-operating income (expense) — 17 — — Impairment charge from classification as assets held for sale — — — — Loss from discontinued operations $ (2,889 ) $ (2,186 ) $ (6,280 ) $ (4,417 ) Additional channel obligations included in discontinued operations in the first half of 2016 is comprised of larger than anticipated rebates of Abstral sales for which we are responsible for through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control. The increase in rebates was partially offset by lower than expect patient assistance program reimbursement. Selling, general and administrative expense included in discontinued operations consists of all other expenses of our commercial operations that are required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the three and months ended June 30,2016 we incurred $2.2 million and $4.6 million respectively, in selling, general, and administrative expense in discontinued operations. of which $2.2 million and $4.4 million , for the three and six months ended June 30, 2016, respectively, related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. These legal proceedings are further disclosed in Part II., Item 1. The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands): June 30, 2016 June 30, 2015 Depreciation and amortization $ — $ 20 Stock-based compensation $ — $ 512 Purchases of property and equipment $ — $ (34 ) Cash paid for acquisition of Zuplenz rights $ — $ (500 )

Business and Basis of Present18

Business and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Discontinued Operations	Discontinued Operations — As described in Note 11, during the quarter ended September 30, 2015 the Company met the relevant criteria for reporting the commercial operations as held for sale and in discontinued operations, pursuant to FASB Topic 205-20, Presentation of Financial Statements - Discontinued Operations, and FASB Topic 360, Property, Plant, and Equipment. During the quarter ended December 31, 2015, the Company completed the sale of the commercial products and the related assets.
Uses of Estimates in Preparation of Financial Statements	Uses of Estimates in Preparation of Financial Statements — The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.
Principles of Consolidation	Principles of Consolidation — The consolidated financial statements include the accounts of Galena and its wholly owned subsidiaries. All material intercompany accounts have been eliminated in consolidation.
Reclassifications	Reclassifications — Certain prior year amounts have been reclassified to conform to current year presentation. These reclassifications had no effect on net loss per share. The Company has reclassified the financial information for the three and six months ended June 30, 2015 to present the Company's commercial business as discontinued operations in the accompanying financial statements as the commercial business was divested in the fourth quarter of 2015.
Cash and Cash Equivalents	Cash and Cash Equivalents — The Company considers all highly liquid debt instruments with an original maturity of 90 days or less to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and demand deposits.
Restricted Cash	Restricted Cash — Restricted cash consists of certificates of deposit on hand with the Company’s financial institutions as collateral for its corporate credit cards and the minimum cash covenant per the Company's outstanding Debentures as described in Note 4.
Fair Value of Financial Instruments	Fair Value of Financial Instruments — The carrying amounts reported in the balance sheet for cash equivalents, accounts receivable, accounts payable, and capital leases approximate their fair values due to their short-term nature and market rates of interest.
Equipment and Furnishings	Equipment and Furnishings — Equipment and furnishings are stated at cost and depreciated using the straight-line method based on the estimated useful lives (generally three to five years) of the related assets.
Goodwill and Intangible Assets	Goodwill and Intangible Assets — Goodwill and indefinite-lived intangible assets are not amortized but are tested annually for impairment at the reporting unit level, or more frequently if events and circumstances indicate impairment may have occurred. Factors the Company considers important that could trigger an interim review for impairment include, but are not limited to, the following: • Significant changes in the manner of its use of acquired assets or the strategy for its overall business; • Significant negative industry or economic trends; • Significant decline in stock price for a sustained period; and • Significant decline in market capitalization relative to net book value. Goodwill and other intangible assets with indefinite lives are evaluated for impairment first by a qualitative assessment to determine the likelihood of impairment. If it is determined that impairment is more likely than not, the Company will then proceed to the two step impairment test. The first step is to compare the fair value of the reporting unit to the carrying amount of the reporting unit. If the carrying amount exceeds the fair value, a second step must be followed to calculate impairment. Otherwise, if the fair value of the reporting unit exceeds the carrying amount, the goodwill is not considered to be impaired as of the measurement date. In its review of the carrying value of the goodwill for its single reporting unit and its indefinite-lived intangible assets, the Company determines fair values of its goodwill using the market approach, and its indefinite-lived intangible assets using the income approach. Intangible assets not considered indefinite-lived are reviewed for impairment when facts or circumstances suggest that the carrying value of these assets may not be recoverable. The Company’s policy is to identify and record impairment losses, if necessary, on intangible assets when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts. In connection with the interim analysis of the PRESENT Phase 3 clinical trial and subsequent close down of the trial, the Company performed an impairment analysis of the intangible asset and goodwill. The fair value was determined to exceed to the carrying amount as of June 30, 2016 based on the other ongoing and and planned trials with NeuVax. As a result, no impairment was deemed necessary to these assets as of June 30, 2016.
Acquisitions and In-Licensing	Acquisitions and In-Licensing — For all in-licensed products and technologies, we perform an analysis to determine whether we hold a variable interest or a controlling financial interest in a variable interest entity. On the basis of our interpretations and conclusions, we determine whether the acquisition falls under the purview of variable interest entity accounting and if so, consider the necessity to consolidate the acquisition. As of June 30, 2016 , we determined there were no variable interest entities required to be consolidated. We also perform an analysis to determine if the assets and liabilities acquired in an acquisition qualify as a "business." The excess of the purchase price over the fair value of the net assets acquired can only be recognized as goodwill in a business combination. The Company completes its valuation analysis no later than twelve months from the date of the acquisition.
Contingent Purchase Price Consideration	Contingent Purchase Price Consideration — Contingent consideration in business combinations is recorded at the estimated fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period with any adjustments in fair value included in our consolidated statement of comprehensive loss.
Patents and Patent Application Costs	Patents and Patent Application Costs — Although the Company believes that its patents and underlying technology have continuing value, the amount of future benefits to be derived from the patents is uncertain. Patent costs are, therefore, expensed as incurred.
Litigation Settlement Payable and Insurance Recoveries	Litigation Settlement Payable and Insurance Recoveries — There can be a significant time lag between the time that legal fees are incurred and the insurance reimbursement available to offset the related costs. The legal costs are recorded in the period they are incurred, and the insurance recoveries for those costs are recorded in the period when the insurance reimbursement is deemed probable.
Share-based Compensation	Share-based Compensation — The Company follows the provisions of the FASB ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees, non-employee directors, and consultants, including stock options and warrants. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is recognized as an expense over the requisite service period. For stock options and warrants granted as consideration for services rendered by non-employees, the Company recognizes compensation expense in accordance with the requirements of FASB ASC Topic 505-50 (“ASC 505-50”), Equity Based Payments to Non- Employees . Non-employee option and warrant grants that do not vest immediately upon grant are recorded as an expense over the vesting period. At the end of each financial reporting period prior to vesting, the value of these options and warrants, as calculated using the Black-Scholes option-pricing model, is re-measured using the fair value of the Company’s common stock and the non-cash compensation recognized during the period is adjusted accordingly. Since the fair market value of options and warrants granted to non-employees is subject to change in the future, the amount of the future compensation expense will include fair value re-measurements until the stock options are fully vested.
Research and Development Expenses	Research and Development Expenses — Research and development costs are expensed as incurred. Included in research and development costs are wages, benefits and other operating costs, facilities, supplies, external services and overhead related to our research and development departments, and clinical trial expenses. Clinical trial expenses include direct costs associated with contract research organizations (CROs), as well as patient-related costs at sites at which our trials are being conducted. Direct costs associated with our CROs are generally payable on a time and materials basis, or when certain enrollment and monitoring milestones are achieved. Expense related to a milestone is recognized in the period in which the milestone is achieved or in which we determine that it is more likely than not that it will be achieved. The invoicing from clinical trial sites can lag several months. We accrue these site costs based on our estimate of upfront set-up costs upon the screening of the first patient at each site, and the patient related costs based on our knowledge of patient enrollment status at each site.
Income Taxes	Income Taxes — The Company recognizes liabilities or assets for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements in accordance with FASB ASC 740-10, Accounting for Income Taxes (“ASC 740-10”). These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled. ASC 740-10 requires that a valuation allowance be established when management determines that it is more likely than not that all or a portion of a deferred asset will not be realized. The Company evaluates the realizability of its net deferred income tax assets and valuation allowances as necessary, at least on an annual basis. During this evaluation, the Company reviews its forecasts of income in conjunction with other positive and negative evidence surrounding the realizability of its deferred income tax assets to determine if a valuation allowance is required. Adjustments to the valuation allowance will increase or decrease the Company’s income tax provision or benefit. The recognition and measurement of benefits related to the Company’s tax positions requires significant judgment, as uncertainties often exist with respect to new laws, new interpretations of existing laws, and rulings by taxing authorities. Differences between actual results and the Company’s assumptions or changes in the company’s assumptions in future periods are recorded in the period they become known. There was no income tax expense or benefit for the three and six month periods ended June 30, 2016 and 2015. We continue to maintain a full valuation allowance against our net deferred tax assets.
Concentrations of Credit Risk	Concentrations of Credit Risk — Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances in several accounts with two banks, which at times are in excess of federally insured limits. As of June 30, 2016 , the Company’s cash equivalents were invested in money market mutual funds. The Company’s investment policy does not allow investment in any debt securities rated less than “investment grade” by national ratings services. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company maintains significant cash and cash equivalents at two financial institutions that are in excess of federally insured limits.
Comprehensive Loss	Comprehensive Loss — Comprehensive loss consists of our net loss, with no other comprehensive income items for the periods presented.
Effect of Recent Accounting Pronouncements	Effect of Recent Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update No. 2016-02, Leases ("ASU 2016-02"). ASU 2016-02 provides accounting guidance for both lessee and lessor accounting models. Among other things, lessees will recognize a right-of-use asset and a lease liability for leases with a duration of greater than one year. For income statement purposes, ASU 2016-02 will require leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern. The new standard will be effective for us on January 1, 2019 and will be adopted using a modified retrospective approach which will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures, however, we anticipate recognition of additional assets and corresponding liabilities related to leases on our balance sheet upon adoption. In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation-Stock Compensation ("ASU 2016-09"). ASU 2016-09 changes several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, employee tax withholding, calculation of shares for use in diluted earnings per share, and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. Early adoption is available. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.
Fair Value Measurement	Fair Value Measurements The Company follows ASC 820, Fair Value Measurements and Disclosures , (“ASC 820”) for the Company’s financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and are re-measured and reported at fair value at least annually using a fair value hierarchy that is broken down into three levels. Level inputs are defined as follows: Level 1 — quoted prices in active markets for identical assets or liabilities. Level 2 — other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date. Level 3 — significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date. The Company categorized its cash equivalents as Level 1. The valuations for Level 1 were determined based on a “market approach” using quoted prices in active markets for identical assets. Valuation of these assets does not require a significant degree of judgment. The Company categorized its warrants potentially settleable in cash as Level 2 inputs. The warrants are measured at market value on a recurring basis and are being marked to market each quarter-end until they are completely settled. The warrants are valued using an appropriate pricing model, using assumptions consistent with our application of ASC 718. The contingent purchase price consideration is categorized as Level 3 inputs and is measured at its estimated fair value on a recurring basis and is adjusted at each quarter-end until it is completely settled. The contingent purchase price consideration is valued based on the expected timing of milestones, the expected probability of success for each milestone and discount rates based on a corporate debt interest rate index publicly issued.
Earnings per Share	Net Income (Loss) Per Share

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis	The following tables present information about our assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets (in thousands): Description June 30, 2016 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 18,169 $ 18,169 $ — $ — Total assets measured and recorded at fair value $ 18,169 $ 18,169 $ — $ — Liabilities: Warrants potentially settleable in cash $ 9,264 $ — $ 9,264 $ — Contingent purchase price consideration 815 — — 815 Total liabilities measured and recorded at fair value $ 10,079 $ — $ 9,264 $ 815 Description December 31, 2015 Quoted Prices In Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Unobservable Inputs (Level 3) Assets: Cash equivalents $ 29,171 $ 29,171 $ — $ — Total assets measured and recorded at fair value $ 29,171 $ 29,171 $ — $ — Liabilities: Warrants potentially settleable in cash $ 14,518 $ — $ 14,518 $ — Contingent purchase price consideration 6,142 — — 6,142 Total liabilities measured and recorded at fair value $ 20,660 $ — $ 14,518 $ 6,142
Reconciliation of Level 3 Liabilities	A reconciliation of the beginning and ending Level 3 liabilities for the six months ended June 30, 2016 is as follows (in thousands): Fair Value Measurements Using Significant Unobservable Inputs (Level 3) Balance, January 1, 2016 $ 6,142 Change in the estimated fair value of the contingent purchase price consideration (5,327 ) Balance at June 30, 2016 $ 815

Accrued Expenses and Other Cu20

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2016
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following (in thousands): June 30, 2016 December 31, 2015 Clinical trial costs $ 3,208 $ 3,294 Professional fees 560 435 Compensation and related benefits 935 1,535 Interest expense — 28 Accrued expenses and other current liabilities $ 4,703 $ 5,292

Legal Proceedings, Commitment21

Legal Proceedings, Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Litigation Settlements	The litigation settlements are summarized as follow as of June 30, 2016 (in thousands) Amount Class action settlement $ 20,000 Derivative settlement 5,000 Shareholders securities litigation settlements $ 1,800 Total settlements $ 26,800 Paid by the insurance carriers $ 21,700 Payable by the company in cash (paid in July 2016) 2,450 Payable by the company in common stock (paid in July 2016) 2,650 Total settlements $ 26,800

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Common Stock are Reserved for Future Issuance	March 2015 Underwritten Public Offering - On March 18, 2015 the Company closed an underwritten public offering of 24,358,974 units at a price to the public of $1.56 per unit for gross proceeds of $38 million (the "March 2015 Offering"). Each unit consists of one share of common stock, and a warrant to purchase 0.50 of a share of common stock at an exercise price of $2.08 per share. The March 2015 Offering included an over-allotment option for the underwriters to purchase an additional 3,653,846 shares of common stock and/or warrants to purchase up to 1,826,923 shares of common stock. On March 18, 2015, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of 1,826,923 shares of common stock. On April 10, 2015, the underwriters exercised their over-allotment option to purchase 3,653,846 shares of common stock for additional net proceeds of $5.4 million . The total net proceeds of the March 2015 Offering, including the exercise of the over-allotment option to purchase the warrants, were $40.8 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. January 2016 Underwritten Public Offering - On January 12, 2016 the Company closed an underwritten public offering of 19,772,727 units at a price to the public of $1.10 per unit for gross proceeds of $21.8 million (the "January 2016 Offering"). Each unit consists of one share of common stock, and a warrant to purchase 0.60 of a share of common stock at an exercise price of $1.42 per share. The January 2016 Offering included an over-allotment option for the underwriters to purchase an additional 2,965,909 shares of common stock and/or warrants to purchase up to 1,779,545 shares of common stock. On January 12, 2016, the underwriters exercised their over-allotment option to purchase warrants to purchase an aggregate of 1,779,545 shares of common stock. The underwriters did not exercise their over-allotment option to purchase 2,965,909 shares of our common stock. The total net proceeds of the January 2016 Offering, including the exercise of the over-allotment option to purchase the warrants, were $20.2 million , after deducting underwriting discounts and commissions and offering expense paid by the Company. Shares of common stock for future issuance are reserved for as follows (in thousands): As of June 30, 2016 Warrants outstanding 37,418 Stock options outstanding 10,309 Options reserved for future issuance under the Company’s 2007 Incentive Plan 10,923 Shares reserved for future issuance under the Employee Stock Purchase Plan 461 Total reserved for future issuance 59,111

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2016
Warrants and Rights Note Disclosure [Abstract]
Schedule of Warrant Activity	The following is a summary of warrant activity for the six months ended June 30, 2016 (in thousands): January 2016 Warrants March 2015 Warrants September 2013 Warrants December 2012 Warrants Other Equity Financing Warrants Warrants issued to Consultants and Debtors Total Outstanding, January 1, 2016 — 14,006 3,973 3,031 816 482 22,308 Issued 13,643 — — — — 2,000 15,643 Exercised — — — — (502 ) — (502 ) Expired — — — — (31 ) — (31 ) Outstanding, June 30, 2016 13,643 14,006 3,973 3,031 283 2,482 37,418 Expiration January 2021 March 2020 September 2018 December 2017 Varies 2016-2017 Varies 2014-2021
Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model	The fair value of the warrants is estimated using an appropriate pricing model with the following inputs: As of June 30, 2016 January 2016 Warrants March 2015 Warrants September 2013 Warrants December 2012 Warrants April 2011 Warrants March 2010 Warrants Strike price $ 1.42 $ 2.08 $ 2.50 $ 1.75 $ 0.65 $ 1.92 Expected term (years) 4.52 3.72 2.22 1.48 0.81 0.25 Volatility % 113.70 % 122.36 % 139.26 % 167.41 % 218.93 % 218.93 % Risk-free rate % 0.94 % 0.82 % 0.61 % 0.51 % 0.42 % 0.19 % As of December 31, 2015 March 2015 Warrants September 2013 Warrants December 2012 Warrants April 2011 Warrants March 2011 Warrants* March 2010 Warrants Strike price $ 2.08 $ 2.50 $ 1.83 $ 0.65 $ 0.65 $ 2.02 Expected term (years) 4.22 2.72 1.98 1.31 0.18 1.00 Volatility % 75.85 % 74.70 % 76.37 % 65.60 % 47.98 % 71.41 % Risk-free rate % 1.58 % 1.24 % 1.05 % 0.77 % — % — %
Changes in Fair Value of Warrant Liability	The changes in fair value of the warrant liability for the six months ended June 30, 2016 were as follows (in thousands): January 2016 Warrants March 2015 Warrants September 2013 Warrants December 2012 Warrants April 2011 Warrants Other Equity Financing Warrants Total Warrant liability, January 1, 2016 $ — $ 10,337 $ 1,933 $ 1,565 $ 537 $ 146 $ 14,518 Fair value of warrants issued 5,590 — — — — — 5,590 Fair value of warrants exercised — — — — (278 ) (46 ) (324 ) Change in fair value of warrants (1,515 ) (6,668 ) (1,148 ) (909 ) (184 ) (96 ) (10,520 ) Warrant liability, June 30, 2016 $ 4,075 $ 3,669 $ 785 $ 656 $ 75 $ 4 $ 9,264

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Allocated Stock-based Compensation Expense	The following table summarizes the components of stock-based compensation expense in the condensed consolidated statements of comprehensive loss for the three and six months ended June 30, 2016 and 2015, respectively (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Research and development $ 108 $ 93 $ 235 $ 170 General and administrative 514 296 1,043 590 Total stock-based compensation from continuing operations $ 622 $ 389 $ 1,278 $ 760
Assumptions for Option Grants Issued	The Company uses the Black-Scholes option-pricing model and the following weighted-average assumptions to determine the fair value of all its stock options granted: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Risk free interest rate 1.41 % 1.69 % 1.41 % 1.50 % Volatility 76.30 % 73.32 % 75.63 % 74.20 % Expected lives (years) 6.25 5.76 6.25 6.09 Expected dividend yield — % — % — % — %
Stock Option Activity	The following table summarizes option activity of the Company: Total Number of Shares (In Thousands) Weighted Average Exercise Price Aggregate Intrinsic Value (In Thousands) Outstanding at January 1, 2016 13,262 $ 2.58 Granted 166 1.27 Exercised (167 ) 1.57 $ 56 Canceled (2,952 ) 3.07 $ — Outstanding at June 30, 2016 10,309 $ 2.44 $ — Options exercisable at June 30, 2016 5,970 $ 2.97 $ —

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Basic and diluted earnings per share are calculated as follows: Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Numerator: Net income (loss) (in thousands) $ 5,389 $ (15,660 ) $ (11,104 ) $ (26,197 ) Denominator: Weighted average number of common shares outstanding 182,034,593 161,383,398 180,703,456 148,647,581 Effect of dilutive securities Stock options 677,279 — — — Warrants 2,765,458 — — — Dilutive potential common shares 3,442,737 — — — Shares used in calculating diluted earnings per share 185,477,330 161,383,398 180,703,456 148,647,581 Basic net income (loss) per share $ 0.03 $ (0.10 ) $ (0.06 ) $ (0.18 ) Diluted net income (loss) per share $ 0.03 $ (0.10 ) $ (0.06 ) $ (0.18 )
Common Shares Excluded from Net Loss	The following table sets forth the potentially dilutive common shares excluded from the calculation of net income (loss) per common share because their inclusion would be anti-dilutive (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Warrants to purchase common stock 21,517 22,308 37,418 22,308 Options to purchase common stock 6,442 11,411 10,309 11,411 Total 27,959 33,719 47,727 33,719

Discontinued Operations, Asse26

Discontinued Operations, Assets Held for Sale (Tables)	6 Months Ended
	Jun. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures	The following table presents amounts related to the discontinued operations in the balance sheets (in thousands): June 30, 2016 December 31, 2015 Carrying amounts of assets included as part of discontinued operations: Accounts receivable, net $ 83 $ 392 Total current assets of discontinued operations, net 83 392 Carrying amounts of liabilities included as part of discontinued operations: Accounts payable $ 1,299 $ 1,491 Accrued expenses and other current liabilities 2,428 4,434 Total current liabilities of discontinued operations $ 3,727 $ 5,925 The following table represents the components attributable to the commercial operations that are presented in the condensed consolidated statements of operations as discontinued operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2016 2015 2016 2015 Net revenue $ — $ 3,382 $ — $ 6,132 Additional channel obligations (656 ) — (1,666 ) — Cost of revenue — (468 ) — (861 ) Amortization of certain acquired intangible assets — (442 ) — (588 ) Research and development — (94 ) — (179 ) Selling, general, and administrative (2,233 ) (4,581 ) (4,614 ) (8,921 ) Non-operating income (expense) — 17 — — Impairment charge from classification as assets held for sale — — — — Loss from discontinued operations $ (2,889 ) $ (2,186 ) $ (6,280 ) $ (4,417 ) Additional channel obligations included in discontinued operations in the first half of 2016 is comprised of larger than anticipated rebates of Abstral sales for which we are responsible for through the end of the first quarter of 2016. The increase in rebates was driven by larger than expected volumes through these rebate channels and additional price protection provisions over which the Company has no control. The increase in rebates was partially offset by lower than expect patient assistance program reimbursement. Selling, general and administrative expense included in discontinued operations consists of all other expenses of our commercial operations that are required in order to market and sell our marketed products. These expenses include all personnel related costs, marketing, data, consulting, legal, and other outside services necessary to support the commercial operations. During the three and months ended June 30,2016 we incurred $2.2 million and $4.6 million respectively, in selling, general, and administrative expense in discontinued operations. of which $2.2 million and $4.4 million , for the three and six months ended June 30, 2016, respectively, related to legal fees from external counsel associated with document production for the subpoenas related to the sales and marketing practices of Abstral. These legal proceedings are further disclosed in Part II., Item 1. The following table presents significant operating non-cash items and capital expenditures related to discontinued operations (in thousands): June 30, 2016 June 30, 2015 Depreciation and amortization $ — $ 20 Stock-based compensation $ — $ 512 Purchases of property and equipment $ — $ (34 ) Cash paid for acquisition of Zuplenz rights $ — $ (500 )

Business and Basis of Present27

Business and Basis of Presentation (Additional Information) (Detail) - USD ($)	Jul. 13, 2016	Jan. 12, 2016	Mar. 18, 2015	Jun. 30, 2015	Jun. 30, 2016	Jul. 29, 2016	May 10, 2016	May 09, 2016	Dec. 31, 2015	Dec. 31, 2014	May 08, 2013
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents				$ 45,279,000	$ 19,590,000				$ 29,730,000	$ 23,650,000
Restricted cash					$ 24,401,000				$ 401,000
Highly-liquid debt instruments maturity days				90 days
Issuance of common stock, shares		19,772,727	24,358,974
Stock purchase price per share (usd per share)		$ 1.10
Exercise price (usd per share)		$ 1.42	$ 2.08				$ 1.51				$ 2.47
Minimum [Member] | Equipment and Furnishings [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives					3 years
Maximum [Member] | Equipment and Furnishings [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Estimated useful lives					5 years
Senior Secured Debentures [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Debt instrument, face amount					$ 25,500,000
Restriction of funds, period (in days)					75 days
Subsequent Event [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Proceeds from issuance of warrants	$ 11,700,000
Exercise price (usd per share)	$ 0.65					$ 0.43		$ 1.51
Subsequent Event [Member] | Senior Secured Debentures [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Debt instrument, face amount								$ 25,530,000
Subsequent Event [Member] | Common Stock [Member]
Schedule Of Summary Of Significant Accounting Policies [Line Items]
Issuance of common stock, shares	28,000,000
Stock purchase price per share (usd per share)	$ 0.45
New warrants issued during period (in shares)	14,000,000

Business Combinations (Details)

Business Combinations (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 5,898	$ 5,898

Fair Value Measurements (Contin

Fair Value Measurements (Contingent Purchase Price Consideration, Measured at Estimated Fair Value on Recurring Basis) (Detail) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Liabilities:
Warrants potentially settleable in cash	$ 9,264	$ 14,518
Unobservable Inputs (Level 3) [Member]
Liabilities:
Contingent purchase price consideration	815	6,142
Fair Value, Measurements, Recurring [Member]
Assets:
Cash equivalents	18,169	29,171
Total assets	18,169	29,171
Liabilities:
Warrants potentially settleable in cash	9,264	14,518
Contingent purchase price consideration	815	6,142
Total liabilities	10,079	20,660
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]
Assets:
Cash equivalents	18,169	29,171
Total assets	18,169	29,171
Liabilities:
Warrants potentially settleable in cash	0	0
Contingent purchase price consideration	0	0
Total liabilities	0	0
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Assets:
Cash equivalents	0	0
Total assets	0	0
Liabilities:
Warrants potentially settleable in cash	9,264	14,518
Contingent purchase price consideration	0	0
Total liabilities	9,264	14,518
Fair Value, Measurements, Recurring [Member] | Unobservable Inputs (Level 3) [Member]
Assets:
Cash equivalents	0	0
Total assets	0	0
Liabilities:
Warrants potentially settleable in cash	0	0
Contingent purchase price consideration	815	6,142
Total liabilities	$ 815	$ 6,142

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation of Level 3 Liabilities) (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Change in the estimated fair value of the contingent purchase price consideration	$ (5,497)	$ (83)	$ (5,327)	$ 238
Unobservable Inputs (Level 3) [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance Liabilities			6,142
Change in the estimated fair value of the contingent purchase price consideration			5,327
Ending Balance Liabilities	$ 815		$ 815

Accrued Expenses and Other Cu31

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Clinical trial costs	$ 3,208	$ 3,294
Professional fees	560	435
Compensation and related benefits	935	1,535
Interest expense	0	28
Accrued expenses and other current liabilities	$ 4,703	$ 5,292

Long-term Debt (Details)

Long-term Debt (Details)	May 10, 2016day$ / sharesshares	May 09, 2016USD ($)$ / sharesshares	May 08, 2013USD ($)$ / sharesshares	Jul. 29, 2016$ / shares	Jul. 13, 2016$ / shares	Jun. 30, 2016USD ($)shares	Jun. 29, 2016$ / shares	Jan. 12, 2016$ / shares	Dec. 31, 2015shares	Mar. 18, 2015$ / sharesshares
Debt Instrument [Line Items]
Term for interest only payments			12 months
Interest payments at the fixed coupon rate			8.45%
Warrants outstanding | shares						37,418,000			22,308,000
Exercise price (usd per share) | $ / shares	$ 1.51		$ 2.47					$ 1.42		$ 2.08
Warrant term			7 years
Cash final payment percentage			5.50%
Term for principal and interest payments			30 months
Cash facility fee percentage			1.00%
Number of shares availabe from warrants | shares										1,826,923
Duration of average market price used for warrant exercise price			20 days
Maximum [Member]
Debt Instrument [Line Items]
Number of shares availabe from warrants | shares			182,186
First Tranche [Member]
Debt Instrument [Line Items]
Loan, amount | $			$ 10,000,000
Subsequent Event [Member]
Debt Instrument [Line Items]
Warrants outstanding | shares		1,000,000
Exercise price (usd per share) | $ / shares		$ 1.51		$ 0.43	$ 0.65
Warrant term		5 years
Number of shares availabe from warrants | shares		2,000,000
Debt Instrument, Covenant, Liquidity Covenant | $		$ 24,000,000
Senior Secured Debentures [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount | $						$ 25,500,000
Senior Secured Debentures [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Redemption period (days) | day	3
Discount to the prior trading day’s volume weighted average price	7.50%
Warrants outstanding | shares	1,000,000
Exercise price (usd per share) | $ / shares							$ 0.43
Senior Secured Debentures [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Interest payments at the fixed coupon rate		9.00%
Debt Instrument, Principal That Could Be Redeemed | $		$ 1,100,000
Debt Instrument, Redemption Price, Percentage		7.50%
Proceeds from Issuance of Secured Debt | $		$ 23,400,000
Dent Instrument, Original Issue Discount, Percent		6.375%
Debt Instrument, Face Amount | $		$ 25,530,000
Debt Instrument, Placement Agent Fee, Percent of Funds Received		2.00%

Legal Proceedings, Commitment33

Legal Proceedings, Commitments and Contingencies Details (Details) - USD ($) $ in Thousands	Jul. 06, 2016	Jul. 01, 2016	Jun. 24, 2016	Jul. 31, 2016	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016
Loss Contingencies [Line Items]
Payable by the insurance carriers								$ 21,700
Total settlements						$ 1,800	$ 0	1,800	$ 0	$ (26,800)
Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]
Loss Contingencies [Line Items]
Total settlements								5,000
Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]
Loss Contingencies [Line Items]
Total settlements								20,000
Payments for legal settlements, paid by insurance								$ 21,700
Scenario, Forecast [Member]
Loss Contingencies [Line Items]
Payable by the company in cash (paid in July 2016)					$ 2,450
Settled Litigation [Member] | Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]
Loss Contingencies [Line Items]
Legal fees			$ 4,500
Payable by the insurance carriers			$ 15,000
Stock option cancellation in period (in shares)			1,200,000
Settled Litigation [Member] | Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]
Loss Contingencies [Line Items]
Legal fees			$ 4,500
Total settlements			$ 20,000
Settled Litigation [Member] | Securities Litigation, Opt Out Settlement, Case 1 [Member]
Loss Contingencies [Line Items]
Total settlements				$ 150
Litigation settlement, issuance of common stock, value				$ 150
Litigation settlement, issuance of common stock (in shares)				291,262
Settled Litigation [Member] | Securities Litigation, Opt Out Settlement, Case 2 [Member]
Loss Contingencies [Line Items]
Litigation settlement, issuance of common stock, value				$ 1,500
Litigation settlement, issuance of common stock (in shares)				3,366,750
Settled Litigation [Member] | Subsequent Event [Member] | Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]
Loss Contingencies [Line Items]
Payments for legal settlements, paid by insurance		$ 16,700
Payable by the company in cash (paid in July 2016)		$ 2,300
Litigation settlement, issuance of common stock, value	$ 1,000				$ 1,000
Litigation settlement, issuance of common stock (in shares)	480,053

Legal Proceedings, Commitment34

Legal Proceedings, Commitments and Contingencies (Schedule of Litigation Settlements) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended
	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016
Loss Contingencies [Line Items]
Total settlements		$ (1,800)	$ 0	$ (1,800)	$ 0	$ 26,800
Payable by the insurance carriers				21,700
Galena Biopharma, Inc. Securities Litigation, Civil Action No. 3:14-cv-00367-SI [Member]
Loss Contingencies [Line Items]
Total settlements				(20,000)
Galena Biopharma, Inc. Derivative Litigation, Civil Action No. 3:14-cv-00382-SI [Member]
Loss Contingencies [Line Items]
Total settlements				(5,000)
Shareholders Securities Litigation [Member]
Loss Contingencies [Line Items]
Total settlements				$ (1,800)
Scenario, Forecast [Member]
Loss Contingencies [Line Items]
Payable by the company in cash (paid in July 2016)	$ 2,450
Payable by the company in common stock (paid in July 2016)	$ 2,650

Stockholders' Equity (Additiona

Stockholders' Equity (Additional Information) (Detail) - USD ($)	Jan. 12, 2016	Apr. 10, 2015	Mar. 18, 2015	Nov. 18, 2014	Apr. 10, 2015	Jun. 30, 2016	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2014	Jul. 14, 2016	May 10, 2016	Dec. 31, 2015	May 08, 2013
Class of Stock [Line Items]
Preferred stock, shares authorized						5,000,000	5,000,000					5,000,000
Preferred stock, par value (usd per share)						$ 0.0001	$ 0.0001					$ 0.0001
Common stock, shares authorized			3,653,846			275,000,000	275,000,000			350,000,000		275,000,000
Common stock, par value (usd per share)						$ 0.0001	$ 0.0001					$ 0.0001
Common stock, additional shares authorized										75,000,000
Proceeds from Issuance or Sale of Equity			$ 38,000,000				$ 78,000	$ 110,000
Purchase Agreement Term				36 months
Share Price			$ 1.56
Issuance of common stock, shares	19,772,727		24,358,974
Number of Shares Per Unit			0.50
Exercise price (usd per share)	$ 1.42		$ 2.08								$ 1.51		$ 2.47
Number of shares availabe from warrants			1,826,923
Stock Issued During Period, Shares, Overallotment Option		3,653,846	1,826,923
Proceeds From Issuance or Sale of Equity, Net Underwriting Discounts, Commissions and Offering Expenses	$ 20,200,000	$ 5,400,000			$ 40,800,000
Stock purchase price per share (usd per share)	$ 1.10
Stock Issued During Period, Value, New Issues	$ 21,800,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.60
Lincoln Park Capital, LLC [Member]
Class of Stock [Line Items]
Proceeds from Issuance or Sale of Equity				$ 4,900,000		$ 4,400,000
Stock Issued During Period, Shares, Purchase of Assets				2,500,000
Share Price				$ 2
Issuance of common stock, shares						2,700,000
Lincoln Park Capital, LLC [Member] | Common Stock [Member]
Class of Stock [Line Items]
Proceeds from Issuance or Sale of Equity				$ 50,000,000
Issuance of common stock, shares				631,221
MLV & Co. LLC and Maxim Group LLC [Member]
Class of Stock [Line Items]
Proceeds from Issuance or Sale of Equity						$ 2,300,000
Issuance of common stock, shares						1,400,000
At Market Issuance Sales Agreements, Percent of Gross Proceeds												3.00%
At Market Issuance Sales Agreements, Maximum Gross Proceeds									$ 20,000,000
Over-Allotment Option [Member]
Class of Stock [Line Items]
Stock Available for Issuance, Shares, New Issues	2,965,909
Number of shares availabe from warrants	1,779,545

Stockholders' Equity (Common St

Stockholders' Equity (Common Stock are Reserved for Future Issuance) (Detail) - shares shares in Thousands	Jun. 30, 2016	Dec. 31, 2015
Equity [Abstract]
Warrants outstanding	37,418	22,308
Stock options outstanding	10,309	13,262
Options reserved for future issuance under the Company's 2007 Incentive Plan	10,923
Shares reserved for future issuance under the Employee Stock Purchase Plan	461
Total reserved for future issuance	59,111

Warrants (Schedule of Warrant A

Warrants (Schedule of Warrant Activity) (Detail) - shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance		22,308
Granted		15,643
Exercised			502
Class of Warrant or Right, Expired		(31)
Warrants outstanding , Ending balance		37,418
January 2016 Warrants [Member]
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance		0
Granted		13,643
Exercised		0
Class of Warrant or Right, Expired		0
Warrants outstanding , Ending balance		13,643
Expiration		Jan. 12, 2021
March 2015 Warrants [Member]
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance		14,006
Granted		0
Exercised		0
Class of Warrant or Right, Expired		0
Warrants outstanding , Ending balance		14,006
Expiration		Mar. 18, 2020
September 2013 Warrant [Member]
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance		3,973
Granted		0
Exercised			0
Class of Warrant or Right, Expired			0
Warrants outstanding , Ending balance		3,973
Expiration		Sep. 18, 2018
December 2012 Warrants [Member]
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance		3,031
Granted		0
Exercised			0
Class of Warrant or Right, Expired			0
Warrants outstanding , Ending balance		3,031
Expiration		Dec. 31, 2017
April 2011 Warrants [Member]
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance		816
Granted		0
Exercised			502
Class of Warrant or Right, Expired			(31)
Warrants outstanding , Ending balance		283
Consultant Warrants [Member]
Class of Warrant or Right, Outstanding [Roll Forward]
Warrants outstanding , Beginning balance		482
Granted		2,000
Exercised			0
Class of Warrant or Right, Expired		0
Warrants outstanding , Ending balance		2,482
Consultant Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Outstanding [Roll Forward]
Expiration	Dec. 31, 2014
Consultant Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Outstanding [Roll Forward]
Expiration	Dec. 31, 2020

Warrants (Fair Value of Warrant

Warrants (Fair Value of Warrants is Estimated Using Black-Scholes Option Pricing Model) (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2014	Dec. 31, 2015
January 2016 Warrants [Member]
Class of Warrant or Right [Line Items]
Strike price	$ 1.42
Expected term (years)	4 years 6 months 7 days
Volatility %	113.70%
Risk-free rate %	0.94%
March 2015 Warrants [Member]
Class of Warrant or Right [Line Items]
Strike price	$ 2.08		$ 2.08
Expected term (years)	3 years 8 months 19 days	4 years 2 months 19 days
Volatility %	122.36%		75.85%
Risk-free rate %	0.82%		1.58%
September 2013 Warrant [Member]
Class of Warrant or Right [Line Items]
Strike price	$ 2.50		$ 2.50
Expected term (years)	2 years 2 months 19 days	2 years 8 months 19 days
Volatility %	139.26%		74.70%
Risk-free rate %	0.61%		1.24%
December 2012 Warrants [Member]
Class of Warrant or Right [Line Items]
Strike price	$ 1.75		$ 1.83
Expected term (years)	1 year 5 months 23 days	1 year 11 months 23 days
Volatility %	167.41%		76.37%
Risk-free rate %	0.51%		1.05%
April 2011 Warrants [Member]
Class of Warrant or Right [Line Items]
Strike price	$ 0.65		$ 0.65
Expected term (years)	9 months 22 days	1 year 3 months 22 days
Volatility %	218.93%		65.60%
Risk-free rate %	0.42%		0.77%
March 2011 Warrants [Member]
Class of Warrant or Right [Line Items]
Strike price			$ 0.65
Expected term (years)		2 months 5 days
Volatility %			47.98%
Risk-free rate %			0.00%
March 2010 Warrants [Member]
Class of Warrant or Right [Line Items]
Strike price	$ 1.92		$ 2.02
Expected term (years)	3 months	1 year
Volatility %	218.93%		71.41%
Risk-free rate %	0.19%		0.00%

Warrants (Changes in Fair Value

Warrants (Changes in Fair Value of Warrant Liability) (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	$ 14,518
Fair Value of Warrants Granted	5,590
Fair Value Of Warrants Exercised		$ 324
Change in fair value of warrants	(10,520)
Warrant liability, Ending balance	9,264
January 2016 Warrants [Member]
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	0
Fair Value of Warrants Granted	5,590
Fair Value Of Warrants Exercised	0
Change in fair value of warrants	(1,515)
Warrant liability, Ending balance	4,075
March 2015 Warrants [Member]
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	10,337
Fair Value of Warrants Granted	0
Fair Value Of Warrants Exercised	0
Change in fair value of warrants	(6,668)
Warrant liability, Ending balance	3,669
September 2013 Warrant [Member]
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	1,933
Fair Value of Warrants Granted	0
Fair Value Of Warrants Exercised		0
Change in fair value of warrants	(1,148)
Warrant liability, Ending balance	785
December 2012 Warrants [Member]
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	1,565
Fair Value of Warrants Granted	0
Fair Value Of Warrants Exercised		0
Change in fair value of warrants	(909)
Warrant liability, Ending balance	656
April 2011 Warrants [Member]
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	537
Fair Value of Warrants Granted	0
Fair Value Of Warrants Exercised		278
Change in fair value of warrants	(184)
Warrant liability, Ending balance	75
March 2011 Warrants [Member]
Class of Warrant or Right, Fair Value [Roll Forward]
Warrant liability, Beginning balance	146
Fair Value of Warrants Granted	0
Fair Value Of Warrants Exercised		$ 46
Change in fair value of warrants	(96)
Warrant liability, Ending balance	$ 4

Warrants (Warrants Classified a

Warrants (Warrants Classified as Equity) (Details) - $ / shares	Jul. 29, 2016	May 08, 2013	Jul. 13, 2016	May 10, 2016	May 09, 2016	Jan. 12, 2016	Mar. 18, 2015
Class of Warrant or Right [Line Items]
Warrants granted, number of shares (in shares)		1,000,000
Exercise price (usd per share)		$ 2.47		$ 1.51		$ 1.42	$ 2.08
Fair value assumptions, expected volatility rate		77.13%
Fair value assumptions, expected term (in years)		5 years 6 months
Fair value assumptions, risk free interest rate		1.26%
Fair value assumptions, expected dividend rate		0.00%
Fair value of warrants granted (usd per share)		$ 0.87
Subsequent Event [Member]
Class of Warrant or Right [Line Items]
Warrants granted, number of shares (in shares)	1,000,000
Exercise price (usd per share)	$ 0.43		$ 0.65		$ 1.51
Fair value assumptions, expected volatility rate	106.63%
Fair value assumptions, expected term (in years)	5 years 6 months
Fair value assumptions, risk free interest rate	1.35%
Fair value assumptions, expected dividend rate	0.00%
Fair value of warrants granted (usd per share)	$ 0.27

Stock Based Compensation (Alloc

Stock Based Compensation (Allocated Stock-based Compensation) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$ 108	$ 93	$ 235	$ 170
Selling, General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	514	296	1,043	590
Commercial Business Segment [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense			0
Continuing Operations [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$ 622	$ 389	$ 1,278	$ 760

Stock Based Compensation (Assum

Stock Based Compensation (Assumptions for Option Grants Issued) (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk free interest rate	1.41%	1.69%	1.41%	1.50%
Volatility	76.30%	73.32%	75.63%	74.20%
Expected lives (years)	6 years 3 months	5 years 9 months 4 days	6 years 3 months	6 years 1 month 2 days
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Stock Based Compensation (Addit

Stock Based Compensation (Additional Information) (Detail) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2016$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, granted | $ / shares	$ 1.36	$ 0.86
Averages contractual term		10 years
Estimated annualized forfeiture rate for options granted to employees		15.00%
Estimated annualized forfeiture rate for options granted to senior management		8.00%
Unrecognized compensation cost | $		$ 3,755
Operating expenses weighted average period		2 years 9 months 15 days
Shares subject to outstanding common stock options granted		166,000
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average vesting term		4 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Average vesting term		6 years
2007 Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance	26,500,000	26,500,000
Shares subject to outstanding common stock options granted		10,309,000
Shares available for future grants	10,923,000	10,923,000
Vesting periods of options granted		4 years
Options expire from date of grant		10 years
Closing price of the Company's common stock | $ / shares	$ 0.47	$ 0.47

Stock Based Compensation (Stock

Stock Based Compensation (Stock Option Activity) (Detail) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Total Number of Shares, outstanding Beginning Balance | shares	13,262
Stock options activity, Total Number of Shares, Granted | shares	166
Stock options activity, Total Number of Shares, Exercised | shares	(167)
Stock options activity, Total Number of Shares, Cancelled | shares	(2,952)
Total Number of Shares, outstanding Ending Balance | shares	10,309
Total Number of Shares, exercisable | shares	5,970
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Stock options activity, Weighted Average Exercise Price, Beginning balance | $ / shares	$ 2.58
Stock options activity, Weighted Average Exercise Price, Granted | $ / shares	1.27
Stock options activity, Weighted Average Exercise Price, Exercised | $ / shares	1.57
Stock options activity, Weighted Average Exercise Price, Cancelled | $ / shares	3.07
Stock options activity, Weighted Average Exercise Price, Ending balance | $ / shares	2.44
Stock options activity, Weighted Average Exercise Price, exercisable | $ / shares	$ 2.97
Stock options activity, Aggregate Intrinsic Value, Beginning balance | $
Stock options activity, Aggregate Intrinsic Value, Granted | $
Stock options activity, Aggregate Intrinsic Value, Exercised | $	56
Stock options activity, Aggregate Intrinsic Value, Cancelled | $	0
Stock options activity, Aggregate Intrinsic Value, Ending balance | $	0
Stock options activity, Aggregate Intrinsic Value, exercisable | $	$ 0

Other Income (Expense) Table (D

Other Income (Expense) Table (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Other Income and Expenses [Abstract]
Change in fair value of the contingent purchase price liability	$ (5,497)	$ (83)	$ (5,327)	$ 238

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Numerator:
Net income (loss)	$ 5,389	$ (15,660)	$ (11,104)	$ (26,197)
Denominator:
Weighted average number of common shares outstanding	182,034,593	161,383,398	180,703,456	148,647,581
Effect of dilutive securities
Stock options	677,279	0	0	0
Warrants	2,765,458	0	0	0
Dilutive potential common shares	3,442,737	0	0	0
Shares used in calculating diluted earnings per share	185,477,330	161,383,398	180,703,456	148,647,581

Net Loss Per Share (Common Shar

Net Loss Per Share (Common Shares Excluded from Net Loss) (Detail) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share	27,959	33,719	47,727	33,719
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share	21,517	22,308	37,418	22,308
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares of common stock issuable upon the exercise which were excluded from the computation of diluted earnings per share	6,442	11,411	10,309	11,411

License Agreements (Additional

License Agreements (Additional Information) (Detail) - USD ($)	Dec. 24, 2015	Dec. 16, 2015	Nov. 19, 2015
Sentynl Therapeutics, Inc. [Member]
License And Collaboration Agreements [Line Items]
Purchase Agreement, Consideration Receivable Under Agreement			$ 12,000,000
Purchase Agreement, Upfront Payment Receivable Under Agreement			8,000,000
Purchase Agreement, Contingent Consideration Receivable Under Agreement			4,000,000
Sentynl Therapeutics, Inc. [Member] | Minimum [Member]
License And Collaboration Agreements [Line Items]
Purchase Agreement, Contingent Consideration Threshold, Net Sales			25,000,000
Sentynl Therapeutics, Inc. [Member] | Maximum [Member]
License And Collaboration Agreements [Line Items]
Purchase Agreement, Contingent Consideration Threshold, Net Sales			$ 35,000,000
Monosol Rx, LLC [Member]
License And Collaboration Agreements [Line Items]
Purchase Agreement, Payment of Upfront Fee		$ 900,000
Purchase Agreement, Payment of Upfront Fee, Percentage of Future Milestone Payments Received		20.00%
Midatech Pharma PLC [Member]
License And Collaboration Agreements [Line Items]
Purchase Agreement, Consideration Receivable Under Agreement	$ 29,750,000
Purchase Agreement, Upfront Payment Receivable Under Agreement	3,750,000
Purchase Agreement, Contingent Consideration Receivable Under Agreement	26,000,000
Midatech Pharma PLC [Member] | Minimum [Member]
License And Collaboration Agreements [Line Items]
Purchase Agreement, Contingent Consideration Threshold, Net Sales	12,000,000
Midatech Pharma PLC [Member] | Maximum [Member]
License And Collaboration Agreements [Line Items]
Purchase Agreement, Contingent Consideration Threshold, Net Sales	$ 70,000,000

Discontinued Operations, Asse49

Discontinued Operations, Assets Held for Sale (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Commercial Business Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, General and Administrative Expense	$ 2,233,000	$ 4,581,000	$ 4,614,000	$ 8,921,000
Success fee contingently due to third party	$ 900,000		$ 900,000
Disposal Group, Including Discontinued Operation, Contingent Liability From Divestiture Agreement, Percent of Realized Future Revenue	5.00%		5.00%
Retention fees contingently due	$ 352,000		$ 352,000
Retention fees contingently due (as percentage of consideration received)	3.00%		3.00%
Abstral and Zuplenz [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Revenue Milestone, Potential Future Milestone Payments	$ 30,000,000		$ 30,000,000
Legal Expenses [Member] | Commercial Business Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, General and Administrative Expense	$ 2,200,000		$ 4,400,000

Discontinued Operations, Asse50

Discontinued Operations, Assets Held for Sale - Net Proceeds from Sale (Details) - USD ($) $ in Thousands	Dec. 24, 2015	Nov. 19, 2015
Abstral [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total consideration		$ 8,348
Less selling costs		(815)
Proceeds from sale, net of selling costs		$ 7,533
Zuplenz [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total consideration	$ 3,750
Less selling costs	(1,050)
Proceeds from sale, net of selling costs	$ 2,700

Discontinued Operations, Asse51

Discontinued Operations, Assets Held for Sale - Carrying Amounts of Assets and LIabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total current liabilities of discontinued operations	$ 3,727		$ 3,727		$ 5,925
Commercial Business Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net	83		83		392
Impairment charge from classification as assets held for sale	0	$ 0	0	$ 0
Total current assets of discontinued operations, net	83		83		392
Accounts payable	1,299		1,299		1,491
Accrued expenses and other current liabilities	2,428		2,428		4,434
Total current liabilities of discontinued operations	$ 3,727		$ 3,727		$ 5,925

Discontinued Operations, Asse52

Discontinued Operations, Assets Held for Sale - Components Attributable to Commercial Business (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations	$ (2,889)	$ (2,186)	$ (6,280)	$ (4,417)
Commercial Business Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenue	0	3,382	0	6,132
Additional channel obligations	(656)	0	(1,666)	0
Cost of revenue	0	(468)	0	(861)
Amortization of certain acquired intangible assets	0	(442)	0	(588)
Research and development	0	(94)	0	(179)
Selling, general, and administrative	(2,233)	(4,581)	(4,614)	(8,921)
Non-operating income (expense)	0	17	0	0
Impairment charge from classification as assets held for sale	0	0	0	0
Loss from discontinued operations	$ (2,889)	$ (2,186)	$ (6,280)	$ (4,417)

Discontinued Operations, Asse53

Discontinued Operations, Assets Held for Sale - Significant Operating Non-cash and Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization expense			$ 777	$ 181
Non-cash stock-based compensation			1,278	759
Purchases of property and equipment			(6)	(34)
Commercial Business Segment [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Impairment of assets held for sale	$ 0	$ 0	0	0
Depreciation and amortization expense			0	20
Allocated share based compensation expense			0
Non-cash stock-based compensation				512
Purchases of property and equipment			0	(34)
Cash paid for acquisition of Zuplenz rights			$ 0	$ (500)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Aug. 08, 2016	Jul. 13, 2016	May 09, 2016	Jan. 12, 2016	Mar. 18, 2015	May 08, 2013	Jul. 29, 2016	Jun. 30, 2016	May 10, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Issuance of common stock, shares				19,772,727	24,358,974
Stock purchase price per share (usd per share)				$ 1.10
Exercise price (usd per share)				$ 1.42	$ 2.08	$ 2.47			$ 1.51
Number of shares availabe from warrants					1,826,923
Interest payments at the fixed coupon rate						8.45%
Warrant term						7 years
Warrants outstanding								37,418,000		22,308,000
Reserved for future issuance								59,111,000
Share Price					$ 1.56
Subsequent Event [Member]
Subsequent Event [Line Items]
Exercise price (usd per share)		$ 0.65	$ 1.51				$ 0.43
Warrant exercise period (in years)		5 years
Proceeds from issuance of warrants		$ 11,700,000
Number of shares availabe from warrants			2,000,000
Warrant term			5 years
Warrants outstanding			1,000,000
Debt Instrument, Covenant, Liquidity Covenant			$ 24,000,000
Senior Secured Debentures [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount								$ 25,500,000
Senior Secured Debentures [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Dent Instrument, Original Issue Discount, Percent			6.375%
Debt Instrument, Face Amount			$ 25,530,000
Proceeds from Issuance of Secured Debt			$ 23,400,000
Interest payments at the fixed coupon rate			9.00%
Debt Instrument, Principal That Could Be Redeemed			$ 1,100,000
Debt Instrument, Redemption Price, Percentage			7.50%
Debt Instrument, Placement Agent Fee, Percent of Funds Received			2.00%
Common Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Issuance of common stock, shares		28,000,000
Stock purchase price per share (usd per share)		$ 0.45
New warrants issued during period (in shares)		14,000,000
Private Placement [Member]
Subsequent Event [Line Items]
Reserved for future issuance								400,000
Private Placement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Reserved for future issuance	500,000
Share Price	$ 0.50
Maximum consideration received on transaction under Purchase Agreement	$ 2,000,000
Maximum [Member]
Subsequent Event [Line Items]
Number of shares availabe from warrants						182,186
Maximum [Member] | Private Placement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Allowable ownership interest under Purchase Agreement	4.99%
Maximum [Member] | Sale Of Stock, Tranche One [Member] | Private Placement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Reserved for future issuance	750,000
Maximum [Member] | Sale Of Stock, Tranche Two [Member] | Private Placement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Reserved for future issuance	1,000,000
Minimum [Member] | Sale Of Stock, Tranche One [Member] | Private Placement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Share Price	$ 0.40
Minimum [Member] | Sale Of Stock, Tranche Two [Member] | Private Placement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Share Price	$ 0.75